Re: RESEARCH: Axonal regeneration in spinal cord injury

[Guest guest]

Hi Mark,

Thanks for the information. We get closer and closer. Thank God it's coming

soon! I believe.

God Bless

Yolanda

RESEARCH: Axonal regeneration in spinal cord injury

Neutralization of CD95 ligand promotes regeneration

and functional recovery after spinal cord injury.

Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes

B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M,

Edler L, Krammer PH, -Villalba A.

Tumor Immunology Program, German Cancer Research

Center, 69120 Heidelberg, Germany.

The clinical outcome of spinal cord injury (SCI)

depends in part on the extent of secondary damage, to

which apoptosis contributes. The CD95 and tumor

necrosis factor (TNF) ligand/receptor systems play an

essential role in various apoptotic mechanisms. To

determine the involvement of these ligands in

SCI-induced damage, we neutralized the activity of

CD95 ligand (CD95L) and/or TNF in spinal cord-injured

mice. Therapeutic neutralization of CD95L, but not of

TNF, significantly decreased apoptotic cell death

after SCI. Mice treated with CD95L-specific antibodies

were capable of initiating active hind-limb movements

several weeks after injury. The improvement in

locomotor performance was mirrored by an increase in

regenerating fibers and upregulation of

growth-associated protein-43 (GAP-43). Thus,

neutralization of CD95L promoted axonal regeneration

and functional improvement in injured adult animals.

This therapeutic strategy may constitute a potent

future treatment for human spinal injury.

SOURCE: Nat Med. 2004 Mar 7 Epub 2004 Mar 07.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=PubMed & list_uids=1\

5004554 & dopt=Abstract

[Guest guest]

Hi Mark - I remember at one time you said you went to see a Doctor, I think in

Massachusetts I think his name was . Well anyway, can you tell me correct

name and what hospital he is in. I know he is doing research also, and if I am

right I believe you mentioned he was your Dr. Can you give me more information

about him. Thank you for your time..... Joan

RESEARCH: Axonal regeneration in spinal cord injury

Neutralization of CD95 ligand promotes regeneration

and functional recovery after spinal cord injury.

Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes

B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M,

Edler L, Krammer PH, -Villalba A.

Tumor Immunology Program, German Cancer Research

Center, 69120 Heidelberg, Germany.

The clinical outcome of spinal cord injury (SCI)

depends in part on the extent of secondary damage, to

which apoptosis contributes. The CD95 and tumor

necrosis factor (TNF) ligand/receptor systems play an

essential role in various apoptotic mechanisms. To

determine the involvement of these ligands in

SCI-induced damage, we neutralized the activity of

CD95 ligand (CD95L) and/or TNF in spinal cord-injured

mice. Therapeutic neutralization of CD95L, but not of

TNF, significantly decreased apoptotic cell death

after SCI. Mice treated with CD95L-specific antibodies

were capable of initiating active hind-limb movements

several weeks after injury. The improvement in

locomotor performance was mirrored by an increase in

regenerating fibers and upregulation of

growth-associated protein-43 (GAP-43). Thus,

neutralization of CD95L promoted axonal regeneration

and functional improvement in injured adult animals.

This therapeutic strategy may constitute a potent

future treatment for human spinal injury.

SOURCE: Nat Med. 2004 Mar 7 Epub 2004 Mar 07.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=PubMed & list_uids=1\

5004554 & dopt=Abstract

[Guest guest]

Hi Joan~

My neurologist is Brown, Jr., MD, PhD, of Mass General

Hospital, in Boston. To schedule an appointment, call Becky Correa,

.

Mark

> Hi Mark - I remember at one time you said you went to see a

Doctor, I think in Massachusetts I think his name was . Well

anyway, can you tell me correct name and what hospital he is in. I

know he is doing research also, and if I am right I believe you

mentioned he was your Dr. Can you give me more information about

him. Thank you for your time..... Joan

> RESEARCH: Axonal regeneration in spinal

cord injury

>

>

> Neutralization of CD95 ligand promotes regeneration

> and functional recovery after spinal cord injury.

>

> Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes

> B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M,

> Edler L, Krammer PH, -Villalba A.

>

> Tumor Immunology Program, German Cancer Research

> Center, 69120 Heidelberg, Germany.

>

> The clinical outcome of spinal cord injury (SCI)

> depends in part on the extent of secondary damage, to

> which apoptosis contributes. The CD95 and tumor

> necrosis factor (TNF) ligand/receptor systems play an

> essential role in various apoptotic mechanisms. To

> determine the involvement of these ligands in

> SCI-induced damage, we neutralized the activity of

> CD95 ligand (CD95L) and/or TNF in spinal cord-injured

> mice. Therapeutic neutralization of CD95L, but not of

> TNF, significantly decreased apoptotic cell death

> after SCI. Mice treated with CD95L-specific antibodies

> were capable of initiating active hind-limb movements

> several weeks after injury. The improvement in

> locomotor performance was mirrored by an increase in

> regenerating fibers and upregulation of

> growth-associated protein-43 (GAP-43). Thus,

> neutralization of CD95L promoted axonal regeneration

> and functional improvement in injured adult animals.

> This therapeutic strategy may constitute a potent

> future treatment for human spinal injury.

>

> SOURCE: Nat Med. 2004 Mar 7 Epub 2004 Mar 07.

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=PubMed & list_uids=15004554 & dopt=Abstract

>

>

>

>

>

>

[Guest guest]

Thank you so much for your information - I will let you know what ever update I

find - T/Y Joan

RESEARCH: Axonal regeneration in spinal

cord injury

>

>

> Neutralization of CD95 ligand promotes regeneration

> and functional recovery after spinal cord injury.

>

> Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes

> B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M,

> Edler L, Krammer PH, -Villalba A.

>

> Tumor Immunology Program, German Cancer Research

> Center, 69120 Heidelberg, Germany.

>

> The clinical outcome of spinal cord injury (SCI)

> depends in part on the extent of secondary damage, to

> which apoptosis contributes. The CD95 and tumor

> necrosis factor (TNF) ligand/receptor systems play an

> essential role in various apoptotic mechanisms. To

> determine the involvement of these ligands in

> SCI-induced damage, we neutralized the activity of

> CD95 ligand (CD95L) and/or TNF in spinal cord-injured

> mice. Therapeutic neutralization of CD95L, but not of

> TNF, significantly decreased apoptotic cell death

> after SCI. Mice treated with CD95L-specific antibodies

> were capable of initiating active hind-limb movements

> several weeks after injury. The improvement in

> locomotor performance was mirrored by an increase in

> regenerating fibers and upregulation of

> growth-associated protein-43 (GAP-43). Thus,

> neutralization of CD95L promoted axonal regeneration

> and functional improvement in injured adult animals.

> This therapeutic strategy may constitute a potent

> future treatment for human spinal injury.

>

> SOURCE: Nat Med. 2004 Mar 7 Epub 2004 Mar 07.

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=PubMed & list_uids=15004554 & dopt=Abstract

>

>

>

>

>

>